Acquisitions - Additional Information (Details) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2026 |
Sep. 30, 2025 |
Sep. 30, 2026 |
Sep. 30, 2025 |
|
| Business Combination [Line Items] | ||||
| Research and development expense recognized | $ 50,617 | $ 40,162 | $ 149,521 | $ 134,488 |
| Takeda Pharmaceutical Company Limited | Balipodect | ||||
| Business Combination [Line Items] | ||||
| Business acquisition consideration | 10,400 | |||
| Research and development expense recognized | 10,400 | |||
| Takeda Pharmaceutical Company Limited | Balipodect | Maximum | ||||
| Business Combination [Line Items] | ||||
| Eligible milestone payments payable | $ 260,000 | $ 260,000 | ||
| X | ||||||||||
- Definition Eligible milestone payments. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|